This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Molinaro, G. Articles by Adam, A. Search for Related Content PubMed PubMed Citation Articles by Molinaro, G. Articles by Adam, A. Related Collections ACE/Angiotension receptors Acute Stroke Syndromes Thrombolysis

(Stroke. 2002;33:1712.)
© 2002 American Heart Association, Inc.

Research Report

Biochemical Basis of Angioedema Associated With Recombinant Tissue Plasminogen Activator Treatment

An In Vitro Experimental Approach

Giuseppe Molinaro, MSc; Nicole Gervais, BSc Albert Adam, PhD

From the Faculté de Pharmacie, Université de Montréal, Montréal (Québec), Canada.

Reprint requests to Albert Adam, PhD, Faculté de pharmacie, Université de Montréal, 2900 boulevard Édouard-Montpetit, C.P. 6128, succursale Centre-ville, Montréal (Québec) H3C 3J7, Canada. E-mail albert.adam{at}umontreal.ca

Abstract

Background— Angioedema has been reported during recombinant tissue plasminogen activator (rtPA) treatment of acute ischemic stroke, often with concomitant use of angiotensin I–converting enzyme inhibitor treatment. Angioedema has been partly attributed to the nonapeptide bradykinin (BK), although its precise role has been poorly documented until now. The purposes of this report are 2-fold. First, we sought to define and characterize the in vitro kinin-forming capacity of rtPA when incubated with human plasma at a concentration within the therapeutic concentration range of rtPA attained in blood in vivo during fibrinolysis. Second, we sought to define the mechanism by which rtPA liberates BK from purified human single-chain high-molecular-weight kininogen, a key constituent of the contact system of plasma and the precursor of BK.

Summary of Report— When incubated with human plasma, in the presence of an angiotensin I–converting enzyme inhibitor, rtPA generates BK, which is further metabolized to des-Arg⁹-BK. The quantity of kinins generated by rtPA is similar to that observed during the activation of the contact system of plasma with a negatively charged surface, suggesting that it is physiologically relevant. The total amount of des-Arg⁹-BK liberated during the incubation period depends on the aminopeptidase P activity, its main degrading peptidase. Additionally, incubations using purified proteins of the fibrinolytic and the contact system pathways show that the rtPA kinin-forming capacity is mediated by plasmin.

Conclusions— We conclude that rtPA used in vitro at a therapeutic concentration has the capacity to generate significant quantities of kinins from human plasma. This kinin-forming activity depends on the activation of the fibrinolytic pathway. These data suggest that angioedema associated with rtPA treatment of ischemic stroke results directly from plasmin-mediated release of BK.

Key Words: angioneurotic edema • kinins • stroke • tissue plasminogen activator

This article has been cited by other articles:

				C. R. Weiler and R. G. Van Dellen Genetic Test Indications and Interpretations in Patients With Hereditary Angioedema Mayo Clin. Proc., July 1, 2006; 81(7): 958 - 972. [Abstract] [Full Text] [PDF]

				M. D. Hill, T. Lye, H. Moss, P. A. Barber, A. M. Demchuk, N. J. Newcommon, T. L. Green, C. Kenney, A. Cole-Haskayne, and A. M. Buchan Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke Neurology, May 13, 2003; 60(9): 1525 - 1527. [Abstract] [Full Text] [PDF]

				G. Molinaro, M. Cugno, M. Perez, Y. Lepage, N. Gervais, A. Agostoni, and A. Adam Angiotensin-Converting Enzyme Inhibitor-Associated Angioedema Is Characterized by a Slower Degradation of des-Arginine9-Bradykinin J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 232 - 237. [Abstract] [Full Text] [PDF]